In ultrasound, small companies are few and far between; here, capital equipment companies rarely get venture backing, and the diversity of clinical segments that ultrasound serves requires sellers to have both large technical and marketing resources. But small companies like SonoSite, with new high-performing and lower-cost hand-held devices hope to disrupt the big-company, radiology-oriented status quo. The small companies are carving out some new non-radiology markets--guidance for catheter insertion, emergency medicine, Ob/Gyn and primary care--by positioning ultrasound as a new kind of triage tool.
By Mary Stuart
It was early Sunday morning and the emergency room of the Highland General Hospital, an inner-city teaching hospital in Oakland,...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
EFPIA says reforms make the continent less attractive for innovative firms.
US green light will further expand sales of the prostate cancer blockbuster.
As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.
EFPIA says reforms make the continent less attractive for innovative firms.
Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.
